Literature DB >> 19282177

Syntheses of novel high affinity ligands for opioid receptors.

Mark P Wentland1, Rongliang Lou, Qun Lu, Yigong Bu, Christoph Denhardt, Jin Jin, Rakesh Ganorkar, Melissa A VanAlstine, Chengyun Guo, Dana J Cohen, Jean M Bidlack.   

Abstract

A series of novel high affinity opioid receptor ligands have been made whereby the phenolic-OH group of nalbuphine, naltrexone methiodide, 6-desoxonaltrexone, hydromorphone and naltrindole was replaced by a carboxamido group and the furan ring was opened to the corresponding 4-OH derivatives. These furan ring 'open' derivatives display very high affinity for mu and kappa receptors and much less affinity for delta. The observation that these target compounds have much higher receptor affinity than the corresponding ring 'closed' carboxamides significantly strengthens our underlying pharmacophore hypothesis concerning the bioactive conformation of the carboxamide group.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282177      PMCID: PMC2791460          DOI: 10.1016/j.bmcl.2009.02.078

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.

Authors:  John L Neumeyer; Ao Zhang; Wennan Xiong; Xiao-Hui Gu; James E Hilbert; Brian I Knapp; S Stevens Negus; Nancy K Mello; Jean M Bidlack
Journal:  J Med Chem       Date:  2003-11-20       Impact factor: 7.446

2.  Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone.

Authors:  Mark P Wentland; Qun Lu; Rongliang Lou; Yigong Bu; Brian I Knapp; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2005-04-15       Impact factor: 2.823

3.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.

Authors:  P S Portoghese; M Sultana; H Nagase; A E Takemori
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

4.  Agonists--antagonists derived from desomorphine and metopon.

Authors:  L J Sargent; E L May
Journal:  J Med Chem       Date:  1970-11       Impact factor: 7.446

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines.

Authors:  M P Wentland; R Lou; Y Ye; D J Cohen; G P Richardson; J M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2001-03-12       Impact factor: 2.823

7.  3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties.

Authors:  M P Wentland; R Lou; C M Dehnhardt; W Duan; D J Cohen; J M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2001-07-09       Impact factor: 2.823

8.  Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives.

Authors:  M P Wentland; W Duan; D J Cohen; J M Bidlack
Journal:  J Med Chem       Date:  2000-09-21       Impact factor: 7.446

9.  14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties.

Authors:  S Archer; A Seyed-Mozaffari; Q Jiang; J M Bidlack
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

10.  Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.

Authors:  Mark P Wentland; Rongliang Lou; Qun Lu; Yigong Bu; Melissa A VanAlstine; Dana J Cohen; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2008-11-07       Impact factor: 2.823

View more
  24 in total

1.  A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.

Authors:  Lei Sun; David McDonnell; Miao Yu; Vipul Kumar; Lisa von Moltke
Journal:  Clin Drug Investig       Date:  2019-05       Impact factor: 2.859

Review 2.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Authors:  Eduardo R Butelman; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

Review 3.  New Antipsychotic Medications in the Last Decade.

Authors:  Mehak Pahwa; Ahmad Sleem; Omar H Elsayed; Megan Elizabeth Good; Rif S El-Mallakh
Journal:  Curr Psychiatry Rep       Date:  2021-11-29       Impact factor: 5.285

Review 4.  What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials.

Authors:  David J Heal; Jane Gosden
Journal:  Int J Obes (Lond)       Date:  2022-01-07       Impact factor: 5.551

Review 5.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 6.  Naltrexone: Not Just for Opioids Anymore.

Authors:  Daniel Sudakin
Journal:  J Med Toxicol       Date:  2016-03

7.  Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Authors:  Yunyun Yuan; Orgil Elbegdorj; Irina O Beletskaya; Dana E Selley; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2013-07-31       Impact factor: 2.823

8.  Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.

Authors:  Megan J Shram; Bernard Silverman; Elliot Ehrich; Edward M Sellers; Ryan Turncliff
Journal:  J Clin Psychopharmacol       Date:  2015-06       Impact factor: 3.153

9.  Evaluation of opioid modulation in major depressive disorder.

Authors:  Elliot Ehrich; Ryan Turncliff; Yangchun Du; Richard Leigh-Pemberton; Emilio Fernandez; Reese Jones; Maurizio Fava
Journal:  Neuropsychopharmacology       Date:  2014-12-18       Impact factor: 7.853

10.  A DFT and semiempirical model-based study of opioid receptor affinity and selectivity in a group of molecules with a morphine structural core.

Authors:  Tamara Bruna-Larenas; Juan S Gómez-Jeria
Journal:  Int J Med Chem       Date:  2012-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.